

Spectrophotometric Estimation Of Drugs Using N-BromoSuccinamide And Indigo Carmine Couple

M.Sasikala, P.Priyanka,

T.VinodKumar¹andG.Venkateshwarlu*

*De

partment of Chemistry, University college of science, Osmania university, Hyderabad-500007, India.

¹Department of Chemistry, TheUniversity of Dodoma, Dodoma, Tanzania.

ABSTRACT

Simple, specific, accurate and precise UV–visible spectrophotometric methods have been developed for the estimation of five drugs *viz.*, Cetrizine (CET), Esmolol (ESM), Rosuvastatin (ROS), Terazocin (TRZ) and Voriconazole(VOR). These methods involve the addition of a known excess of NBS to the drugs in acid medium followed by estimation of residual NBS by reacting with a fixed amount of Indigo Carmine and measuring the absorbance at 610nm. The proposed methods were found to be successful for the estimation of these drugs in bulk and their formulations. The results of analysis have been validated statistically for linearity, accuracy, precision, LOD and LOQ.

Keywords: Cetrizine, Esmolol, Rosuvastatin, Terazocin, UV-visible spectrophotometry, Validation, Voriconazole.

.....

Corresponding author E-mail: venkateshwarlugoud@yahoo.com

9908153467

INTRODUCTION:

CETRIZINE HYDROCHLORIDE (CET) (Fig.1a) is an orally active and selective H₁-receptor antagonist[1]. Its chemical name is (±) - [2-[4-[(4-chlorophenyl)phenylmethyl]-1-piperazinyl]ethoxy]acetic acid, dihydrochloride. It is a non-sedating type histamine H₁-receptor antagonist used in symptomatic treatment of seasonal rhinitis, conjunctivitis, perennial allergic rhinitis, and pruritus and urticaria of allergic origin. Various analytical techniques have been employed for the determination of CET in pharmaceutical preparations such as spectrophotometry[2],[3], high performance liquid chromatography (HPLC)[3],[4],[5],[6],[7],[8],[9] and liquid chromatography-mass spectrometry (LC/MS)[10],[11], RP-LC[12] and Capillary zone electrophoretic method[13].

ESMOLOL (ESM) (Fig.1b) hydrochloride is a class II antiarrhythmic and is chemically known as methyl (RS)-3-{4-[2-hydroxy-3-(propan-2-ylamino) propoxy] phenyl} propanoate hydrochloride. It is cardio selective beta₁receptor blocker with rapid onset. It is used in the treatment for the rapid control of heart rate. ESM decreases the force and rate of heart contractions by blocking beta-adrenergic receptors[14] of the sympathetic nervous system. The methods which were reported in the literature for the determination of ESM includes HPLC[15],[16],[17],[18],[19], liquid chromatography-mass spectrometry (LC/MS)[20], Capillary zone electrophoretic method[21], Chiral column chromatography[22] and spectrophotometry[23],[24].

ROSUVASTATIN (ROS) (Fig.1c) Rosuvastatin (ROS), bis((E)-7[4-(4-Fluorophenyl)-6-isopropyl-2-(Methyl (methylsulfonyl) aminopyrimidin-5yl)](3R,5S)-3,5-dihydroxyhept-6-enoic acid) Calcium salt. It belongs to the class of drugs called statins which are employed to lower hypercholesterolemia and related conditions and to prevent cardiovascular diseases.[25] It is highly effective 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitor.[1,3-8] In clinical trials, rosuvastatin achieved mark reduction in serum levels of LDL cholesterol, accompanied by modest increases in HDL cholesterol and reduction in triglyceride. The most important related compounds for rosuvastatin are anti isomer and lacton impurity. Literature survey reveals that few Stability-indicating spectrophotometry[26],[27],[28], liquid chromatography [29],[30],[31],[32], HPLC [33], Tandem mass spectrometry[34] and voltammetry[35] methods have been reported.

TERAZOCIN (TRZ) (Fig.1d) is chemically known as RS-1-(4-amino-6, 7-dimethoxy-2-quinazolinyl)-4-[(tetra-hydro-2-furanyl) carbonyl]-piperazinemonohydrochloride. It is a α₁-adrenoceptor blocker with a long lasting action. [36]. It is used in the management of hypertension and in benign prostate hyperplasia to relieve symptoms of urinary obstruction. Terazosin is rapidly and almost completely absorbed from the gastrointestinal tract after oral administration and is extensively metabolized in the liver to yield piperazine and three other

inactive metabolites. Literature review reveals that a few methods have been published for analysis of TRZ in the bulk form and in pharmaceutical preparations. Methods available include HPLC[37],[38],[39][40], Spectrophotometry[41],[42],[43],[44],[45], Visible spectrophotometry[46] and potentiometry [47].

VORICONAZOLE (VOR) (Fig.1e) chemically is (α R, β S)-(2,4-difluorophenyl)-5-fluoro- β -methyl- α -(1H-1,2,4-triazol-1-yl-methyl)-4-pyrimidine ethanol (Figure 1). It is a second generation broad spectrum triazole introduced to treat fungal infections[48] like invasive aspergillosis, disseminated infections caused by fluconazole resistant candida, fusarium infections and febrile neutropenia not responding to antibacterial therapy and its primary mode of action is by inhibition of the fungal cytochrome P450 dependent 14α -steroid methylase, an essential enzyme in ergosterol biosynthesis. Up to now there are many methods developed like HPLC[49],[50],[51][52],[53], HPTLC[54],[55],[56], LC-MS[57],[58], Colorimetry[59], UPLC-MS[60] and UV spectrophotometric [61] methods developed.

A comparison of various techniques used for estimation of above drugs in terms of sensitivity and reproducibility are presented in Table-1.

Thorough survey of literature revealed that simple spectrophotometric methods are not yet reported for the above drugs. In this communication we present simple, accurate, precise methods for the quantification of above drugs.

MATERIALS AND METHODS

The pharmaceutical grade drugs were supplied by Aurbindo Pharmaceuticals and Hetero drugs Pvt. Ltd, Hyderabad. Indigo Carmine, HCl were purchased from S.d fine chem. Pvt. Ltd, Mumbai, India. N-Bromosuccinamide (NBS) is purchased from SRL chemicals, Mumbai, India. Whatman filter paper no.42 was used for filtration purpose. All the reagents used were of analytical-reagent grade and distilled water was used throughout the investigation. Tablets were purchased from the local market.

All absorbance measurements were recorded on an Elico 210 double beam spectrophotometer, Systronics 117 spectrophotometer and also on ELICO 159 UV-VIS single beam spectrophotometers using quartz cells of 10 mm path length. A high precision Analytical (Dhona 200 single pan electrical) balance was used for weighing the reagents.

Preparation of Standard stock solutions:

N-Bromosuccinamide (NBS): An approximately 0.01M solution was prepared by dissolving 0.1779 g of NBS in 100 ml distilled water. It is diluted to get $124\mu\text{g mL}^{-1}$ of NBS.

Indigo Carmine: Stock solution was prepared by dissolving 0.0484g of Indigo Carmine in 100 ml distilled water. From this stock solution, $353\mu\text{g mL}^{-1}$ test solution was prepared.

Hydrochloric acid solution: Conc.HCl is diluted appropriately with distilled water to get 1M HCl solution.

Drugs: A standard solutions of drugs were prepared by dissolving accurately weighed 50 mg of pure drug in water and diluted to the mark in 100 ml calibrated volumetric flasks. The stock solutions of CET, ESM, ROS, TRZ and VOR were diluted with water to obtain 20-140 $\mu\text{g mL}^{-1}$, 1.0-7.0 $\mu\text{g mL}^{-1}$, 4.8-33.6 $\mu\text{g mL}^{-1}$, 1.0-7.0 $\mu\text{g mL}^{-1}$ and 30-210 $\mu\text{g mL}^{-1}$ respectively.

Conc. Hydrochloric acid (HCl): Conc. HCl is diluted appropriately with distilled water to get 1.0 M HCl solution.

Method Development:

Aliquots of pure drug solution (1.0-7.0ml) were transferred into a series of 10ml calibrated flasks. To each flask 1.0ml of 1MHCl acid was added followed by 1.0ml of NBS solution. The flasks are stoppered and contents were mixed and the flasks are set aside for 15 min under occasional shaking. Finally, 1.0 ml of Indigo Carmine solution was added to each flask and the volume was adjusted to the mark with water and mixed well. The absorbance of each solution was measured at 520nm after 5 min.

Construction of Calibration Curve:

Six replicate experiments were performed and the relative response *i.e.*, absorbance / concentration ($\mu\text{g mL}^{-1}$) was calculated. The points falling between 95% and 105% of average only are considered for the construction of calibration. A standard graph was prepared by plotting the absorbance versus the concentration of drugs(Fig.2). The standard deviation of six residual intercepts of the plots is used for calculating LOD and LOQ. Beer's Law is obeyed and calibration curves for CET, ESM, ROS, TRZ, and VOR over a concentration range of 20-140 $\mu\text{g mL}^{-1}$, 1.0-7.0 $\mu\text{g mL}^{-1}$, 4.8-33.6 $\mu\text{g mL}^{-1}$, 1.0-7.0 $\mu\text{g mL}^{-1}$ and 30-210 $\mu\text{g mL}^{-1}$ respectively, were plotted. The spectral and statistical characteristics are recorded in Table-2.

Analysis of Drugs in the Pure form for Precision and Accuracy Studies:

As mentioned, six replicate experiments were performed to ascertain the precision of the methods. The results differed only in a small range of experimental errors.

The accuracy of the proposed methods was evaluated by percentage recovery studies on the drugs. The %RSD was ≥ 2 , showing high degree of accuracy of the proposed methods. The effect of excipients on the methods developed was also tested and found that excipients do not interfere much. The results of the method lie within the prescribed limits showing that method is free from interference from excipients. The results of the recovery studies together with other statistical parameters are reported in Table-3.

Analysis of commercial Dosage forms:

A quantity of finely ground powder of tablets of equivalent to 50 mg of drug CET (Citrazine), ESM (Minibloc), ROS (Crestor), TRZ (Hytrin) and VOR(Vorzu), were accurately weighed and taken in 60 ml distilled water in 100 ml volumetric flask and left for 10 min for complete dispersion and then filtered through Whatman filter paper. First 10 ml portion of the filtrate was rejected and a convenient aliquot of filtrate was further diluted for the analysis within the limits of Beer's law.

Four different solutions of each drug were analyzed through recovery studies, using the calibration curves constructed. Excellent recovery was observed Table-4.

RESULTS AND DISCUSSION :

N-Bromosuccinamide (NBS) has been used widely as a brominating and oxidizing agent for organic compounds. The proposed methods are indirect and are based on the oxidation and bromination reaction between drug and NBS and determination of residual NBS after allowing the reaction between drug and measured amount of NBS to be complete. The amount of NBS reacted corresponds to the drug content in all the methods.

Drug + known excess of NBS -----» Reaction product of the drug + Unreacted NBS

Unreacted NBS+ Fixed amount of Indigo Carmine-----» Absorbance measured at 520nm.

Method validation:

The proposed methods were validated according to guidelines of International Conference on Harmonization (ICH). Under the described experimental conditions, standard experimental conditions, standard calibration curves for the studied drugs were constructed by plotting absorbance versus concentration. Conformity with Beer's law was evident in the concentration range cited in Table-2. The linear regression equations, molar absorptivity, Sandell's sensitivity, limits of detection (LOD) and limits of quantification (LOQ) were listed in it. Standard deviation, relative standard deviation, variance and standard error were calculated.

The accuracy of the method was established by analyzing the pure drug at four levels (within working limits) and the precision was ascertained by calculating the relative standard deviation of six replicate determinations on the same solution containing the drug at three levels in Table-3. The analytical results for accuracy and precision showed that the proposed methods have good repeatability and reproducibility.

The percentage recoveries of the drugs in tablet using the proposed methods compared with that given by reference methods are illustrated in Table-4. The validity of the proposed method in

literature is evaluated by statistical analysis between the results obtained and that of reference methods. Student's t-test and variance ratio F-test are chosen for the comparison of the results. Values are within the permissible range reported in literature. The tablet formulations were also analyzed to check the applicability of methods.

CONCLUSION :


The obtained results from the method for the determination of mentioned drugs indicate that method is simple, accurate and precise. The method is economical compared to other sophisticated analytical instruments. Hence this method can be used for routine analysis of commercially available formulations. The method is suitable for the determination of these drugs in tablet formulation without interference from commonly used excipients. The solvents used for the method are inexpensive and simple to prepare, and could be used in a quality control laboratory for routine drug analysis.

ACKNOWLEDGEMENTS:


One of the author M.Sasikala is thankful to Chaiman, Princeton College for permission, P.Priyanka is thankful to CSIR for awarding of JRF. We are grateful to Head, Department of Chemistry, Osmania University, for providing facilities.

IJSER


fig1.structure of drugs




1a.cetrizine hydrochloride




1b.Esmolol



1c.Rosuvastatin






1d.Terazosin



1e. Voriconazole

fig2.calibration curves





| Method | Linearity range in | Sensitivity range | Precession %RSD | Accuracy %Recovery | Limitations |
|--------------------------|--------------------------------|-------------------|-----------------|--------------------|------------------|
| HPLC | 0.05-2400 μgmL^{-1} | 0.1432-0.4849 | 0.613-1.899 | 98-101.54 | Costly equipment |
| Electrochemical Methods | 0.05-1000 μM | ----- | ----- | 98.65-100.76 | Low sensitivity |
| Direct Spectrophotometry | 1-400 μgmL^{-1} | 0.0084-0.2186 | 0.34-1.96 | 98.74-101.54 | Involve UV-light |
| Spectrofluorometry | 0.02-30 μgmL^{-1} | ----- | ----- | 98.17-99.17 | Rare equipment |

Table 1 :Comparison of various techniques used for essay of the drus (range of parameters in general)

Table 2: Analytical parameters for determination of drugs by oxidation with NBS and Indigo Carmine

| Property Name of the Drug | CET | ESM | ROS | TER | VOR |
|--|---------------------|---------------------|---------------------|---------------------|---------------------|
| λ_{max} , nm | 610 | 610 | 610 | 610 | 610 |
| Beer's law limits $\mu\text{g mL}^{-1}$ | 20-140 | 1-7 | 4.8-33.6 | 1-7 | 30-210 |
| Molar absorptivity, $\text{L mol}^{-1} \text{cm}^{-1}$ | 2.507×10^3 | 3.690×10^4 | 1.253×10^4 | 4.968×10^4 | 1.510×10^3 |
| Sandell sensitivity* $\mu\text{g cm}^{-2}$ | 0.2000 | 0.0086 | 0.04 34 | 0.0091 | 0.3333 |
| Slope (a) | 0.016 | 0.012 | 0.012 | 0.015 | 0.027 |
| Intercept (b) | 0.005 | 0.115 | 0.023 | 0.109 | 0.003 |
| Correlation coefficient (r) | 0.999 | 0.999 | 0.998 | 0.999 | 0.999 |
| Standard deviation of intercept (Sa) | 0.0091 | 0.0114 | 0.0106 | 0.0109 | 0.0444 |
| Limit of detection $\mu\text{g mL}^{-1}$ | 6.006 | 0.327 | 1.520 | 0.330 | 6.8467 |
| Limit of quantification $\mu\text{g mL}^{-1}$ | 18.00 | 0.991 | 4.608 | 1.000 | 20.747 |
| Regression equation $Y=b+ax$ | $0.005+0.016X$ | $0.115+0.012X$ | $0.023+0.012X$ | $0.109+0.015X$ | $0.003+0.027X$ |

Table 3: Determination of accuracy and precision of the methods on pure drug Samples

| Drug | Taken (µg/ml) | Found (µg/ml) | error (%) | Recovery (%) | RSD(%) | Proposed method Mean ± SD |
|------|---------------|---------------|-----------|--------------|--------|---------------------------|
| CET | 1.5 | 1.51 | 0.66 | 100.66 | 0.6153 | 100.03 ± 0.615 |
| | 2.5 | 2.50 | 0.00 | 100 | | |
| | 3.5 | 3.48 | 0.57 | 99.43 | | |
| ESM | 4.0 | 4.00 | 0.0 | 100.00 | 0.2677 | 99.95 ± 0.267 |
| | 5.0 | 5.01 | 0.20 | 100.20 | | |
| | 6.0 | 5.98 | 0.33 | 99.67 | | |
| ROS | 3.0 | 3.01 | 0.33 | 100.33 | 0.5819 | 99.84 ± 0.581 |
| | 4.0 | 4.0 | 0.00 | 100 | | |
| | 5.0 | 4.96 | 0.80 | 99.20 | | |
| TRZ | 1.5 | 1.50 | 0.00 | 100 | 0.2865 | 99.72 ± 0.286 |
| | 3.5 | 3.48 | 0.57 | 99.43 | | |
| | 4.0 | 3.99 | 0.25 | 99.75 | | |
| VOR | 2.0 | 1.97 | 1.50 | 98.50 | 1.2543 | 99.72 ± 1.254 |
| | 4.0 | 4.04 | 1.0 | 101 | | |
| | 6.0 | 5.98 | 0.33 | 99.67 | | |

Table 4: Results of Assay of Tablets by the proposed methods (Standard amount of drug is added when the content of drug is very low.)

| Tablets | Drug in tablet $\mu\text{g mL}^{-1}$ | Drug added $\mu\text{g mL}^{-1}$ | Total found $\mu\text{g mL}^{-1}$ | er (%) | Recovery (%) | RSD (%) | Reference method Mean \pm SD | Propose method \pm SD | t-test | F-test |
|----------------|--------------------------------------|----------------------------------|-----------------------------------|--------|--------------|---------|--------------------------------|-------------------------|------------------|-----------------|
| CET(Citrazine) | 1.0 | 1.0 | 2.01 | 0.50 | 100.50 | 0.6839 | 99.50 \pm 1.10 | 100.29 \pm 0.685 | 0.565 (2.571) | 0.387 (4.95) |
| | 1.0 | 2.0 | 3.02 | 0.66 | 100.66 | | | | | |
| | 1.0 | 3.0 | 4.01 | 0.25 | 100.25 | | | | | |
| | 1.0 | 0.0 | 0.99 | 1.00 | 99.00 | | | | | |
| | 2.0 | 0.0 | 2.02 | 1.00 | 101.00 | | | | | |
| | 3.0 | 0.0 | 3.01 | 0.33 | 100.33 | | | | | |
| ESM(Minibloc) | 1.0 | 0.5 | 1.5 | 0.00 | 100.00 | 0.5241 | 100.40 \pm 0.25 | 100.05 \pm 0.524 | 0.110 (2.477) | 4.393 (4.28) |
| | 1.0 | 1.0 | 2.01 | 0.50 | 100.50 | | | | | |
| | 1.0 | 1.5 | 2.52 | 0.80 | 100.80 | | | | | |
| | 2.0 | 0.0 | 1.99 | 0.50 | 99.50 | | | | | |
| | 3.0 | 0.0 | 3.00 | 0.00 | 100.00 | | | | | |
| | 4.0 | 0.0 | 3.98 | 0.5 | 99.50 | | | | | |
| ROS (crestor) | 1.0 | 1.0 | 2.02 | 1.00 | 101.00 | 0.5560 | 99.03 \pm 0.290 | 100.20 \pm 0.557 | 1.029 (2.571) | 3.689 (4.95) |
| | 1.0 | 2.0 | 3.00 | 0.00 | 100.00 | | | | | |
| | 1.0 | 3.0 | 3.99 | 0.25 | 99.75 | | | | | |
| | 2.0 | 0.0 | 2.01 | 0.50 | 100.50 | | | | | |
| | 4.0 | 0.0 | 3.98 | 0.50 | 99.50 | | | | | |
| | 6.0 | 0.0 | 6.03 | 0.5 | 100.50 | | | | | |
| TERZ (Hytrin) | 2.0 | 1.5 | 3.49 | 0.28 | 99.72 | 0.2775 | 100.38 \pm 0.58 | 100.07 \pm 0.277 | 1.154 (2.477) | 0.228 (4.28) |
| | 2.0 | 3.0 | 5.01 | 0.20 | 100.20 | | | | | |
| | 2.0 | 4.5 | 6.49 | 0.15 | 99.85 | | | | | |
| | 2.0 | 0.0 | 2.01 | 0.50 | 100.50 | | | | | |
| | 4.0 | 0.0 | 4.00 | 0.00 | 100.00 | | | | | |
| | 6.0 | 0.0 | 6.01 | 0.16 | 100.16 | | | | | |
| VOR (Vorzu) | 1.0 | 1.0 | 2.00 | 0.00 | 100.00 | 0.621 | 99.66 \pm 0.232 | 99.79 \pm 0.620 | 1.354 (3.182) | 0.140 (4.75) |
| | 1.0 | 1.5 | 2.49 | 1.00 | 99.00 | | | | | |
| | 1.0 | 2.0 | 2.98 | 0.66 | 99.34 | | | | | |
| | 2.0 | 0.0 | 1.99 | 0.50 | 99.50 | | | | | |
| | 3.0 | 0.0 | 3.02 | 0.66 | 100.66 | | | | | |
| | 4.0 | 0.0 | 4.01 | 0.25 | 100.25 | | | | | |

REFERENCES:

1. Sevgitatarulu, "Extractive Spectrophotometric Determination of Cetirizine Dihydrochloride in Pure and Pharmaceutical Preparations", *Journal of Food and Drug Analysis*, Vol.18, No.6,pp440-446, 2010.
2. PrachiVKabra, LVG Nargund and MS Murthy, "Development and Validation of a Stability-Indicating LC-UV Method for Simultaneous Determination of Ketotifen and Cetirizine in Pharmaceutical Dosage Forms", *Trop J Pharm Res*, Vol.13, No.7,pp1144, 2014.
3. A. F. M.E Walily, M. A.Korany, A. E Gindy and M. F. Bedair. "Spectrophotometric and High Performance Liquid Chromatographic Determination of Cetirizine Dihydrochloride in Pharmaceutical Tablets", *J. Pharm. Biomed.Anal.* Vol.17,pp 435-442, 1998.
4. Paloma Flórez Borges, Pilar Pérez Lozano, EncarnaGarcía Montoya, Montserrat Miñarro, Josep R Ticó, Enric Jo and Josep M SuñeNegre. "Determination of Stress-Induced Degradation Products of Cetirizine Dihydrochloride By a Stability-Indicating RP-HPLC method", *DARU Journal of Pharmaceutical Sciences*, Vol.22,pp82 -5,2014.
5. A.M.Y. Jaber, H.A. A Sherifeb, M.M. A Omarib, A.A. Badwanb, "Determination of Cetirizine di Hydrochloride, Related Impurities And Preservatives In Oral Solution And Tablet Dosage Forms Using HPLC", *Journal of Pharmaceutical and Biomedical Analysis*, Vol.36, No.2, pp341-350, 2004.
6. C.K.Kim, K.J. Yeon, E.Ban, M.J.Hyun, J.K.Kim, M.K.Kim, S.E.Jin and J.S.Park, "Narrow-Bore High Performance Liquid Chromatographic Method For The Determination Of Cetirizine In Human Plasma Using Column Switching", *J. Pharm. Biomed. Anal.* Vol.37, pp603-609, 2005.
7. EffatSouri, Ali Hatami, NazaninShabaniRavari, FarhadAlvandifar, and MalihehBarazandehTehrani, "Validating a Stability Indicating HPLC Method for Kinetic Study of Cetirizine Degradation in Acidic and Oxidative Conditions", *Iran J Pharm Res.*, Vol.12, No.2, pp287-294, 2013.
8. S.N.Makhija and P.R.Vavia, "Stability Indicating HPTLC Method For The Simultaneous Determination Of Pseudoephedrine And Cetirizine In Pharmaceutical Formulations", *J. Pharm. Biomed. Anal.* vol.25, pp663-667, 2001.
9. T.PradeepKumar ,M. AkifulHaque , K.Prashanth Kumar , G.Nivedita , V.PrakashDiwan, "Simultaneous Determination Of Ceitrizine Hydrochloride and Ambroxol Hydrochloride In

Combined Dosage Form By Using RP-HPLC Method”, *Am. J. PharmTech Res.* Vol. 2, No.6, 2012.

10.S.Rudaz, S. Souverain, C.Schelling, M.Deleers, A.Klomp, A. Norris, T. L. Vu, B. Ariano and J. L. Veuthey, “Development And Validation Of a Heart-Cutting Liquid Chromatography-Mass Spectrometry Method For The Determination Of Process-Related Substances In Cetirizine Tablets”,*Anal. Chim.Acta*, Vol. 492, No.1-2,pp271-282, 2003.

11.Q. Song, H.Junga, Y. Tang,A.C. Li, T. Addison, M.McCort-Tipton,B.Beato, and W.Naidong. Automated 96-well solid phase extraction and hydrophilic interaction liquid chromatography–tandem mass spectrometric method for the analysis of cetirizine (ZYRTEC®) in human plasma–with emphasis onmethod ruggedness. *J. Chromatogr. B* 2005, 814: pp105-114.

12.M.F.Zaater,Y.R.Tahboub, andN.M.Najib, “RP-LC Method For The Determination Of Cetirizine In Serum”, *J. Pharm. Biomed. Anal.*Vol. 22,pp739-744,2000.

13. F. SattaryJavid, A. Shafaat, A. Zarghi. “Determination Of Cetirizine And Its Impurities In Bulk And Tablet Formulation Using a Validated Capillary Zone Electrophoretic Method”, *Journal of Analytical Chemistry*, Vol.69 No.5, pp 442-447,2014.

14.Narayana, C. NarasimhaRao, C. NarasimhaRao, K. Sivakumar,“Spectrophotometric Determination Of Esmolol Hydrochloride Using Analytical Reagents”,*Indian Journal of Advances in Chemical Science*.Vol.2, No.4,pp 289-293, 2014.

15.Yi-Hong Tang, Ying He, Tong-wei Yao, Su Zeng, “Stereo Selective RP-HPLC Determination OfEsmolol Enantiomers In Human Plasma After Pre-Column Derivatization’, *J.Biochem. BiophysMethods*,Vol. 59, No.2, pp159–166, 2004.

16.Nancy N. Karnatz, David M. Baaske, Dale E. Herbranson, Mark S. Eliason,“High-Performance Liquid Chromatographic Method For The Determination Of Esmolol Hydrochloride In Solutions And Parenteral Formulations”,*Journal of Chromatography A*, Vol.330,pp420–424, 1985.

17. Vanitha somasekhar and D. Gowri sankar, Development and Validation of a Rapid RP-HPLC Method for the Estimation of Esmolol Hydrochloride in Bulk and Pharmaceutical Dosage Forms, *E-Journal of Chemistry*, Vol.7,No.3, pp807-812, 2010.

18. Tang YH, He Y, Yao TW, Zeng S, Stereoselective RP-HPLC determination of esmolol enantiomers in human plasma after pre-column derivatization, *J Biochem Biophys Methods*, vol.59, No.2, pp159-66, 2004.

19. Liu, Zhong; Xu, Jun; Zhang, Yi; Chen, Guanrong, Determination Of Esmolol Hydrochloride And Related Substances By HPLC, *Zhongguo Yiyuan Yaoxue Zazhi*, Vol.26, No.1, pp104-106, 2006.

20. Athena F Zuppa, Heng Shia, Peter C Adamson, Liquid chromatography–Electrospray Mass Spectrometry (LC–MS) Method For Determination Of Esmolol Concentration In Human Plasma, *Journal of Chromatography B*, Vol.796, No.2, pp 293–301, 2003.
21. Malovaná S, Gajdošová D, Benedik J and Havel, J, Determination Of Esmolol In Serum By Capillary Zone. Electrophoresis And Its Monitoring In Course Of Heart Surgery, *J Chromatogr B*. Vol.760, pp37-43, 2001.
22. Lei Fang, Crystal Bykowski-Jurkiewicz, Jeffrey G. Sarver, Paul W. Erhardt, “Determination of Esmolol And Metabolite Enantiomers Within Human Plasma Using Chiral Column Chromatography”, *Journal of Chromatography B*. Vol. 878, No.26, pp2449–2452, 2010.
23. Tirupathi Baddenapalli and Venkateshwarlu Gandu, Spectrophotometric Determination Of Drugs Using N-Bromo Succinimide And Rhodamine-B As Analytical Reagent, *World Journal of Pharmaceutical Research*, Vol.4,No.8, pp 1383-1395, 2015.
24. K.Sayanna, G.Venkateshwarlu, “Spectrophotometric determination of drugs and pharmaceuticals by cerium (IV) amaranth dye couple”, *IOSR Journal of Applied Chemistry* Vol. 5, No.4, pp 01-09, 2013.
25. Zahi Mohammad Turabi, O’hood Atef Khatatbeh, “Stability-Indicating RP-HPLC Method Development and Validation for the Determination of Rosuvastatin (Calcium) In Pharmaceutical Dosage Form”, *International Journal of Pharmaceutical Sciences and Drug Research*, Vol.6, No.2, pp 154-159, 2014.
26. Nadia M. Mostafa, Amr M. Badawey, Nesrine T. Lamie, Abd El-Aziz B. Abd El-Aleem. “Stability-indicating methods for the determination of rosuvastatin calcium in the presence of its oxidative degradation products”, *Int J Pharm Biomed Sci*. Vol. 3, No.4, pp193-202, 2012.
27. Najma Sultana, Muhammad Saeed Arayne and Saeeda Nadir Ali, “An Ultra-Sensitive LC Method For Simultaneous Determination Of Rosuvastatin, Alprazolam And Diclofenac Sodium In API, Pharmaceutical Formulations And Human Serum by Programming the Detector”, *Journal of Analytical & Bioanalytical Techniques*. Vol. 3, No.7, 2012, ISSN:2155-9872 JABT, an open access journal.
28. Abdul Aziz Ramadan, Hasna Mandil, Noor Alshelhawi, “Spectrophotometric Determination Of Rosuvastatin Calcium In Pure Form And Its Pharmaceutical Formulations By The Oxidation Using Iodine And Formation Triiodide Complex In Acetonitrile”, *International Journal of Pharmacy and Pharmaceutical Sciences*, Vol.6 No.5, pp 579-585, 2014.

29. Muhammad Ashafaq, Hamad Ahmad, Islam Ullah Khan, and Ghulam Mutafa, "LC Determination Of Rosuvastatin And Ezetimibe In Human Plasma", *J. Chil. Chem. Soc.* Vol.58, No.4, pp2177-2181, 2013.
30. Mukthinuthalapathi Mathrusri Annapurna, Bukkapatnam Venkatesh, and Bandaru. Sai Pavan Kumar, "Stability Indicating Liquid Chromatographic Method For The Simultaneous Determination Of Rosuvastatin And Ezetimibe In Pharmaceutical Formulations", *Adv Pharm Bull.* Vol. 4, No.4, pp405-411, 2014.
31. Mukthinuthalapathi Mathrusri Annapurna, Bukkapatnam Venkatesh, and Bandaru. Sai Pavan Kumar, Naga Supriya Grandhi, "Simultaneous Determination Of Rosuvastatin And Ezetimibe in Pharmaceutical Formulations By Stability Indicating Liquid Chromatographic Method", *Journal of Bioequivalence & Bioavailability*, pp174-180, 2014.
32. H. K. Lee, C. S. Ho, M. Hu, B. Tomlinson and C. K. Wong, "Development And Validation Of a Sensitive Method For Simultaneous Determination Of Rosuvastatin and N-desmethyl Rosuvastatin In Human Plasma Using Liquid Chromatography/Negative Electrospray Ionization/Tandem Mass Spectrometry", *Biomedical Chromatography*, Vol.27, No.11, pp1369-74, 2013.
33. Y. Shah, Z. Iqbal, L. Ahmad Khan, M. I. Khan Nazir, F. Nasir, "Simultaneous Determination Of Rosuvastatin And Atorvastatin In Human Serum Using RP-HPLC/UV Detection: Method Development, Validation And Optimization Of Various Experimental Parameters", *J Chromatogr B Analyt Technol Biomed Life Sci.* Vol.879, No.9-10, pp557-63, 2011.
34. Narapusettia Anjaneyulu, Bethanabhatlac Syama Sundar, Anbazhagan Sockalingam, Repakab Nagakishore, Veldandi Sarithae, "Simultaneous Determination Of Rosuvastatin And Amlodipine In Human Plasma Using Tandem Mass Spectrometry: Application To Disposition Kinetics", *Journal of Advanced Research*, 2014, *J Adv Res* (2014), <http://dx.doi.org/10.1016/j.jare.2014.08.010>.
35. Sacide Altınöz and Banu Uyar, "Electrochemical Behaviour And Voltammetric Determination Of Rosuvastatin Calcium In Pharmaceutical Preparations Using a Square-Wave Voltammetric Method", *Anal. Methods*, Vol.5, pp 5709-5716, 2013.
36. EC Sekhar, TR Rao, KR Sekhar, MU Naidu, JC Shobha, PU Rani, TV Kumar, VP Kumar, "Determination Of Terazosin In Human Plasma, Using High-Performance Liquid Chromatography With Fluorescence Detection", *J Chromatogr B Biomed Sci Appl*, Vol.710, No.1-2, pp137-42, 1998.
37. Alankar Shrivastava and Vipin B. Gupta, Stability-Indicating RP-HPLC Method for the Simultaneous Determination of Prazosin, Terazosin, and Doxazosin in Pharmaceutical Formulations, *scientia pharmaceutica*, Vol.80, No.3, pp 619-631, 2012.

38. Bakshi M, Ojha T, Singh S, Validated Specific HPLC Methods For Determination Of Prazosin, Terazosin and Doxazosin In The Presence Of Degradation Products Formed Under ICH-Recommended Stress Conditions, *J Pharm Biomed Anal*, Vol.34, No.1,pp 19-26, 2004.
39. APZavitsanos, T.Alebic-Kolbah,“ Enantioselective Determination Of Terazosin In Human Plasma By Normal Phase High-Performance Liquid Chromatography-Electrospray Mass Spectrometry”, *J Chromatogr A*.Vol.794, No.1-2, pp 45-56, 1998.
- 40.AlankarShrivastava,“Various Analytical Methods For The Determination Of Terazosin In Different Matrices”,*World Journal of Analytical Chemistry*, Vol.1, No.4,pp 80-86, 2013.
- 41.AlankarShrivastava, VipinBihari Gupta,“Ultra Violet Spectrophotometric Method: Not Possible For The Simultaneous Estimation Of α 1-Adreno Receptor Blockers”,*Journal of Pharmaceutical Negative Results*, Vol.2, No.2, pp 115-120, 2011.
- 42.Joanna Karpinska, AnetaSokol, Marta Wierzbicka, Barbara Starczewska, UrszulaCzyzewska, Marta Hryniewicka,“ Spectrophotometrically And Chemometrically Assisted Studies On The Photo Stability Of Terazosyne In An Aqueous Environment”, *Polish Journal of Environmental Studies*, Vol.21, No.3,pp 667-675, 2012.
- 43.M.Sundarapandian, M.S.Prakash, S.Venkataraman, M.Boopathi, “Extractive Spectrophotometric Determination Of Terazosin”, *International Journal of Chemical Sciences*,Vol.5, No.5,pp 2102-2106, 2007.
44. E. Sheikh Ragaa, S. EsmailNahla , A. Gouda Ayman , Basset WalidAbde,“Extractive Spectrophotometric Determination Of Some α -Adrenergic-Antagonists In Pure Forms And In Pharmaceutical Formulations”, *Chemical Industry & Chemical Engineering Quarterly*, Vol.18, No.2, pp 179-191, 2012.
- 45.K. NagarajaSetty, G. V. Ranga Reddy. N. Rami Reddy, “ Spectrophotometric Determination Of Terazosin In Tablet Dosage Forms”, *World Journal of Pharmaceutical Research*, Vol.4, No.1, pp 875-881,2015.
46. S. PrakashSarsambi,G.K. Kapse and S. AppalaRaju,“Visible Spectrophotometric Determination Of Terazosin Hydrochloride From Bulk Drug And Formulations”, *Asian Journal of Chemistry*, Vol.14, No.1,pp 545-547, 2002.
- 47.Sayed I M. Zayed,Mohamed M. Khalil, Yousry M. Issa, and Huda R. Khalefa,“ Flow Injection Potentiometric Determination Of Terazosin Hydrochloride Using Modified Carbon Paste Electrodes”, *International Journal of Electrochemical Science*,Vol. 9, pp 2327-2340, 2014.
48. P.Sree Ramamurthy,K.Srinivas, YVV.Jogenderkumar, JagadeeshPanda and P.Sandhya Rose, “Development And Validation of RP-HPLC Method For The Estimation of Voriconazole In

Bulk and Pharmaceutical Dosage Form”, *Chemical Science Transactions*, Vol.3, No.4, pp 1576-1582, 2014.

49.K.Sangsiriwut ,M. Chayakulkeeree, “Rapid High Performance Liquid Chromatographic Assay For Determination Of Voriconazole Concentration In Human Plasma”, *Journal of medical association of Thailand*, Vol.96, No.2, pp98-103, 2013.

50. K.Sangsiriwut ,M. Chayakulkeeree, “Rapid High Performance Liquid Chromatographic Assay For Determination Of Voriconazole Concentration In Human Plasma”, *Journal of medical association of Thailand*, Vol. 96, No.2, pp98-103, 2013.

51.S.Nakagawa, “Determination Of The Antifungal Agent Voriconazole In Human Plasma Using a Simple Column -Switching High -Performance Liquid Chromatography And Its Application To a Pharmacokinetic Study”, *Chemical and Pharmaceutical Bulletin*, 2008;Vol.56, No.3, pp328-331, 2008.

52.F.Péhourcq ,C.Jarry ,B. Bannwarth, “Direct Injection HPLC Micro Method For The Determination Of Voriconazole In Plasma Using An Internal Surface Reversed-Phase Column’, *Bio medical chromatography*, Vol.18, No.9, pp719-22, 2004.

53.ClaudiaMichael,JensTeichert,RainerPreiss,“Determination Of Voriconazole In Human Plasma And Saliva Using High-Performance Liquid Chromatography With Fluorescence Detection”,*Journal of Chromatography B*. Vol.865, No.1-2, pp74–80, 2008.

54.B.AmolKhetre,S. Rahul Darekar,K. PurushottamSinha,M. Rajesh Jeswani and C.MrinaliniDamle,“Validated HPTLC Method For Determination Of Voriconazole In Bulk And Pharmaceutical Dosage Form”, *Rasayan J. Chem*, Vol.1, No.3, pp542-547, 2008.

55.V.GandhiSantosh ,KadamAshwini and SuralkarManjula, “Development And Validation Of Stability Indicating HPTLC Method For Determination Of Voriconazole In Pharmaceutical Dosage Form”, *International Journal of Research in Pharmacy and Chemistry*, 2014, Vol.4, No.3, pp564-570,2014.

56.G.MohitDewani, C.TejasBorole,P. Sejal Gandhi, A. R. Madgulkar,C.MrinaliniDamle, “Development And Validation Of HPTLC Method For Determination Of Voriconazole In Human Plasma”, *Der PharmaChemica*, Vol.3, No.4, pp201-209, 2011.

57.B.G.Keevil ,S. Newman ,S. Lockhart,S.J. Howard, C.B.Moore and D.W.Denning, “Validation Of An Assay For Voriconazole In Serum Samples Using Liquid Chromatography-Tandem Mass Spectrometry”, *The Drug Monit*, Vol.26, No.6, pp650-657, 2004.

58.B.V.Araujo , D.J.Conrado,E.C. Palma, T.Dalla Costa, “Validation Of Rapid And Simple LC-MS/MS Method For Determination Of Voriconazole In Rat Plasma”, *J Pharm Biomed Anal*, Vol.44, pp985-990, 2007.

59. RavalKashyap and Kevin Makavana, “ Development Of New Colorimetric method And Validation For Determination Of Voriconazole in Bulk And Marketed Formulation”, *IJRPC* 2013, Vol.3, No.3, pp712-722, 2013.

60.Zhe Wang, Cheng-ke Huang, Wei Sun, Cui Xiao and Zeng-shouWang, “UPLC-MS/MS Determination Of Voriconazole In Human Plasma And Its Application To a Pharmacokinetic Study”, *Biomedical Chromatography*, Vol.29, No.2,pp 188–193, 2015.

61.I.H.AdamsAndréa ,SteppeMartin, E.Fröhlich Pedro, M.BergoldAna, “Comparison Of Microbiological And UV-Spectrophotometric Assays for Determination of Voriconazole in Tablets”, *Journal of AOAC International*, Vol.89, No.4, pp 960, 2006.

IJSER